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Early detection of progressive renal dysfunction in patients with
coronary artery disease.
Background. An association between renal hemodynamic
dysfunction and coronary artery disease (CAD) has been doc-
umented in chronic renal failure; however, no information is
available in CAD patients with normal glomerular filtration rate
(GFR). This study was aimed at evaluating early abnormalities
and outcome of renal function in CAD patients.
Methods. In 15 nondiabetic patients with normal renal func-
tion and no significant stenoses in renal arteries, and having un-
dergone coronary arteriography, we studied systemic and renal
hemodynamics before and after a vasodilating stimulus induced
by aminoacid (AA) infusion. A control group (C) consisted of
15 sex- and age-matched kidney donors. The statistical adequacy
of the sample size was preliminarily verified. Renal clearances
were repeated after two years.
Results. At baseline, GFR (mL/min/1.73 m2) averaged 81.4 ±
3.8 in CAD and 83.7 ± 1.4 in C (P = NS); RPF (mL/min/
1.73 m2) was 297 ± 22 in CAD and 456 ± 15 in C (P < 0.0001);
filtration fraction was higher in CAD (P < 0.001). Plasma renin
activity was higher in CAD (P < 0.005). The number of coronary
stenoses was inversely correlated with RPF but not with GFR.
In CAD, at variance with C, AA did not induce any increment
of GFR, while RPF increased without achieving the unstimu-
lated value of C. Blood pressure was comparable in CAD and C
at baseline and not modified by AA. After two years, a signifi-
cant decrease in GFR (−14%, P < 0.001) and RPF (−15%, P <
0.001) occurred only in CAD, and in either group, the response
to AA did not differ from that detected at baseline.
Conclusion. In CAD patients with normal GFR, reduction in
renal perfusion and absence of renal functional reserve likely
represent early markers of progressive renal dysfunction.
Atherosclerotic involvement of one vascular bed gen-
erally suggests the presence of atherosclerotic damage in
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other districts since the predisposing factors are the same
[1, 2]. The frequent onset of clinical signs and the ele-
vated specificity and sensitivity of the noninvasive tests
for coronary artery disease (CAD) allow a reliable early
diagnosis of CAD [3]. Unfortunately, the same does not
hold true for ischemic renal disease, an increasingly rec-
ognized disorder responsible for about 20% of new cases
of renal failure in advanced age [4–6]. Indeed, chronic
renal hemodynamic dysfunction, at variance with CAD,
often is underdiagnosed because of the slow and unappar-
ent progression of the renal lesions, absence of relevant
serum and urinary abnormalities, and availability of less
specific diagnostic tests [7]. Therefore, such a diagnosis
is generally delayed, being made only in the presence of
renal failure in association with signs of atherosclerotic
disease and/or in the presence of sudden and severe ele-
vation of blood pressure.
Of note, although the relationship of level of renal func-
tion to CAD has been evaluated by studies in patients
with chronic renal failure, even in the absence of hyper-
tension and diabetes [8–12], no information has been pro-
vided on the early phases of renal disease, when GFR is
not impaired. In these patients, the evaluation of renal
hemodynamics is critical to detect an early dysfunction.
Indeed, a valuable tool to identify mild derangements of
renal hemodynamics is represented by renal functional
reserve, measured by inulin and para-aminohyppurate
(PAH) clearances before and after a vasodilating stim-
ulus induced by infusion of aminoacids (AA) [13–15].
Furthermore, for best assessment of the independent ef-
fects of atherosclerotic disease on kidney function, it is
essential to study, as control group, age- and sex-matched
healthy subjects with normal renal function in whom any
known cardiovascular risk factors have been carefully
excluded.
This study was aimed at evaluating in CAD patients
with normal GFR, as compared to healthy kidney donors,
unstimulated and stimulated renal hemodynamics, and
renal outcome.
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METHODS
The study is a prospective controlled trial carried out
at the Departments of Nephrology and Cardiology at
the University of Catanzaro and approved by the local
Ethical Committee.
Selection criteria
The subjects considered eligible for the study were re-
cruited among 123 patients with medical history of CAD,
consecutively referred to the diagnostic cardiac catheter-
ization unit of our hospital during a 10-month period
(October 2001–July 2002) because of the requirement for
coronary angiography according to the recommendations
of the American College of Cardiology [16]. To select
CAD patients in the initial phase of atherosclerotic dis-
ease and with normal renal function, the following inclu-
sion criteria were applied: serum creatinine ≤1.2 (male)
and ≤1.0 (female) mg/dL; normal urine chemistry at dip-
stick and normal sediment; absence of microalbumin-
uria, as currently defined [i.e., abnormal urinary excretion
of albumin (UAE) between 30–300 mg/24 hours, as mea-
sured by enzyme immunoassay] [17, 18]; absence of
significant stenoses (>50% of arterial lumen) of renal
arteries, as assessed by renal selective arteriography per-
formed in the course of coronary angiography; absence
of uncontrolled arterial hypertension (blood pressure, BP
>140/90 mm Hg). Fifteen patients were enrolled into the
study after giving informed consent.
The control (C) group was recruited in the same period,
and age- and sex-matched with the CAD group. All had
proven healthy status; they were, in fact, enrolled from a
group of subjects selected for kidney donation in whom
a comprehensive diagnostic evaluation was carried out
to exclude any known cardiovascular risk factor by stan-
dard clinical, laboratory, and instrumental investigation
as previously reported by our group [15].
All subjects were kept on a standard daily dietary
regimen containing 8.0 g of sodium and 1.0 g/kg body
wt of protein. Compliance to diet was verified by re-
peated determinations of 24-hour sodium and urea ex-
cretion. The study was performed one week after the
achievement of compliance to dietary prescription. Some
patients received nitrates (N = 2), platelet aggregation in-
hibitors (N = 6), angiotensin-converting enzyme (ACE)
inhibitors or angiotensin II receptor antagonists (ARA)
(N = 5), and statins (N = 6). No patient was taking cal-
cium blockers. ACE inhibitors and ARA were withdrawn
one week before the laboratory determinations (includ-
ing urinalysis and microalbuminuria) and renal clearance
studies; a washout of such length was considered suffi-
cient to test the renal hemodynamics according to the
pharmacokinetics of these drugs [19, 20].
Protocol
Body weight, daily urinary sodium, and urea excre-
tion were measured in our hospital in order to verify the
compliance of participants to the prescribed diet. We also
measured the basal serum levels of urea nitrogen, sodium,
potassium, creatinine, glucose, cholesterol, triglycerides,
and peripheral plasma renin activity (PRA) and aldos-
terone. PRA and aldosterone were measured both in
supine and upright position, as previously reported [21].
Ventricular ejection fraction was measured by echocar-
diography as previously reported by our group [14] and
in accord with De Simone et al [22]. Kidney sizes were
measured by renal ultrasound in all participants by the
same physician, who was blinded to the clinical features
of the patients.
A coronary angiographic grading based on the num-
ber and localization of coronary stenoses was provided.
Internal luminal narrowing >50%, detected by quantita-
tive coronary angiography (QCA), in one of the major
coronary arteries or its major branches was considered
significant evidence of coronary heart disease. The an-
giographic investigation was extended to selective arteri-
ography of renal arteries to exclude the presence of renal
artery stenoses. In the renal arteries, as for the assess-
ment of coronary heart disease, internal luminal narrow-
ing greater than 50% was considered as hemodynamically
significant artery stenoses.
All subjects underwent clearance studies to assess renal
plasma flow (RPF) and glomerular filtration rate (GFR)
before and after AA infusion, as previously described
[1, 23]. Specifically, RPF and GFR were determined af-
ter 12-hour fasting by measuring PAH clearance (CPAH)
and inulin clearance (CIN), respectively. PAH (0.8%) and
inulin (1.2%) were infused intravenously in a 5% (W/V)
glucose solution at the constant rate of 1 mL/min to main-
tain plasma concentration of inulin at 10 to 20 mg/dL
and PAH at 1.0 to 2.0 mg/dL. A 5% glucose infusion
(5 mL/min) was added to enhance urinary volume in
order to allow several clearance periods in a relatively
short time. After a 60-minute equilibration period, when
a steady state of urine flow was achieved (i.e., the mag-
nitude of changes in urine volume did not exceed 10%
in three consecutive urine collections), three 30-minute
renal clearances were performed. Thereafter, RPF and
GFR were evaluated during the intravenous infusion of
a 7.5% AA solution (Solamin , Pierrel, Italy) at an in-
fusion rate of 4 mL/min. During this second phase, the
5% glucose infusion was discontinued. Therefore, renal
hemodynamics were studied during the AA infusion un-
der the same conditions of the basal clearances. After a
further 60-minute equilibration period, three 30-minute
renal clearances were performed. At the beginning and at
the end of each clearance period, plasma samples for de-
termination of PAH, inulin, sodium, and potassium were
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obtained. Urine was collected by spontaneous voiding to
determine PAH, inulin, sodium, and potassium. Arterial
blood pressure (BP) and heart rate were monitored every
10 minutes during the study.
Follow-up
A reevaluation of the main clinical and laboratory pa-
rameters was performed after one and two years, with
kidney size reevaluted by the same physician of the basal
study. The renal clearance studies were repeated in CAD
patients after a two year-follow up period in 12 patients
(3 were lost during the follow-up: 2 due to a change in
their residential address and 1 due to worsening of CAD
that required cardiac surgery) and in 10 C (healthy kidney
donors, 5 donated their kidney).
Laboratory procedures
Determinations were obtained in the central labora-
tory of our University Hospital, whose technicians were
not aware of the clinical features of the subjects under
study. UAE was measured with an enzyme-linked im-
munosorbent assay technique in 24-hour samples [18].
Inulin levels were determined by diphenylamine method
and PAH by colorimetric methods, as previously de-
scribed [24]. In all analytical determinations the standard
curves of inulin and PAH were determined by linear re-
gression analysis; the correlation coefficient (r) of these
curves was always greater than 0.994. Replicate mea-
surements of both GFR and RPF in the same individ-
ual showed a coefficient of variation not exceeding 3%
(three repeated measurements). The plasma levels of
urea, creatinine, sodium, potassium, and glucose were
measured by an autoanalyzer (Olympus AU 400; Olym-
pus Italia, Segrate, Italy). PRA and aldosterone were
measured by a radioimmunoassay technique using com-
mercial kits (DPC, Los Angeles, CA, USA). Renal vascu-
lar resistances (RVR, mm Hg/mL/min) were determined
by the ratio of mean arterial pressure and renal blood
flow (RBF = RPF/1 − Ht, where Ht is the hematocrit).
RFR was calculated as the percent increase of CIn and
CPAH versus baseline following AA infusion.
Sample size
The study has been designed to identify a difference of
means equal to one SD with an I type error of 0.05 and
a power of 0.80 at two tail in the decline of creatinine
clearance between the two groups. Ten subjects for each
group had to complete the study.
Statistical analysis
All values are reported as mean ± standard error
(SEM) or as median and range. All clearance data have
been corrected for a body surface area of 1.73 m2.
Nonparametric procedures have been used because of
Table 1. Clinical and laboratory characteristics of controls and CAD
patients at baseline
Controls CAD patients P
Number males 15 (8) 15 (7)
Age years 60.1 ± 3.1 59.8 ± 2.8 NS
Weight kg 76 ± 4.3 77 ± 4.9 NS
BMI kg/m2 25.1 ± 1.3 25.7 ± 1.41 NS
Systolic BP mm Hg 136 ± 1.3 138 ± 1.1 NS
Diastolic BP mm Hg 80 ± 3.3 83 ± 2.2 NS
LV EF% 67.2 ± 3.48 56.9 ± 2.58 <0.05
sCreatinine mg/dL 1.07 ± 0.03 1.06 ± 0.04 NS
sGlucose mg/dL 99.1 ± 4 101 ± 3 NS
TC mg/dL 192 ± 35 205 ± 27 NS
TRG mg/dL 114 ± 10 152 ± 16 <0.05
U-Na mmol/24h 133 ± 5 117 ± 7 NS
GFR mL/min/1.73m2 83.7 ± 1.4 81.4 ± 3.8 NS
RPF mL/min/1.73m2 456 ± 15 297 ± 22 <0.005
FF% 18.5 ± 0.5 28.8 ± 1.7 <0.001
RVR mm Hg/mL/min 0.16 ± 0.01 0.24 ± 0.02 <0.001
PRA supine ng/L/s 0.40 ± 0.01 0.79 ± 0.05 <0.005
PRA upright ng/L/s 0.90 ± 0.06 1.45 ± 0.15 <0.005
Aldosterone supine ng/dL 196 ± 7.1 239 ± 6.4 <0.0001
Aldosterone upright ng/dL 23.6 ± 1.87 38.6 ± 1.63 <0.0001
UAE mg/24h 14.7 ± 0.8 17.3 ± 1.1 NS
Abbreviations are: LV, left ventricular; EF, ejection fraction; TC, total
cholesterol; TRG, triglycerides; FF, filtration fraction; RVR, renal vascular
resistances; PRA, plasma renin activity; UAE, urinary albumin excretion. Data
are mean ± SEM.
the small sample size. Differences were evaluated by
Wilcoxon matched pairs test for paired samples to com-
pare baseline versus post-AA values and to compare the
values obtained at time of angiography with the follow-up
values; Mann-Whitney and Kruskal-Wallis (with Dunns
post-test) tests were used to compare the two cohorts (i.e.,
patients versus C subjects), as appropriate. Linear corre-
lation was also used to evaluate the association between
inulin and creatinine clearances, and baseline values of
RPF and GFR with their respective changes induced by
AA infusion and baseline and 2-year follow-up values of
GFR and RPF. A P < 0.05 was considered statistically
significant.
RESULTS
Demographic and clinical features
The demographic and clinical features of the partic-
ipants are reported in Table 1. The two study groups
were comparable in terms of demographic characteris-
tics and renal function. BP levels were not significantly
different between healthy controls and CAD patients.
PRA was significantly greater in patients (Table 1); sim-
ilarly, plasma aldosterone concentration was normal in
controls and elevated in CAD patients. Microalbumin-
uria (measured after 1 week from ACE inhibitors and
ARA withdrawal) was absent both in controls (ranging 6–
22 mg/24 h) and in CAD patients (ranging 11–26 mg/24h)
(Table 1). The kidney longitudinal diameters, measured
by echography, were significantly lower in CAD patients
than in the controls (10.1 ± 0.3 vs. 11.3 ± 0.8, P < 0.001).
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Fig. 1. Values of basal GFR and RPF accord-
ing to number of significant coronary stenoses
(SCS). (Kruskal Wallis analysis with Dunn’s
multiple comparison test).
As reported in Table 1, the ejection fraction is about 15%
lower in CAD patients than in C subjects at baseline.
In order to evaluate whether a decline in ejection frac-
tion would be expected to result in changes in renal and
hormonal function, the values of GFR, RPF, PRA, and
plasma aldosterone were compared in each subject af-
ter adjusting for ejection fraction. This correction did not
modify the differences between the two groups.
An abnormal coronary arteriogram was obtained in all
CAD patients. In particular, in 12 patients one or more
significant coronary stenoses were found. In the remain-
ing three patients two or more not significant stenoses
(<50%) were detected; however, a diagnosis of coronary
artery disease could be made also in these cases because
they complained of typical chest pain and were positive to
the treadmill test. Coronary angioplasty with stenting was
performed in four patients using percutaneous standard
femoral approach, according to cardiologic evaluation.
During arterial catheterization, patients underwent
renal arteriography; this showed, in 11 patients, mild
atherosclerotic lesions of the main renal arteries in con-
junction with atherosclerosis changes of the aorta. When
present, however, these lesions were of low grade.
Renal clearance studies
As shown in Table 1, patients with CAD had a basal
GFR comparable to that of healthy subjects, while RPF
was considerably reduced (P < 0.005 vs. healthy subjects).
A direct highly significant correlation between inulin and
creatinine clearance (r = 0.997; P < 0.005) was found.
Consequently, the filtration fraction was much higher in
CAD patients (P < 0.001). CAD patients also exhibited
greater RVR values (P < 0.001). A significant association
between the number of significant coronary stenoses and
RPF, but not GFR, was found (Fig. 1).
The infusion of AA did not influence either arterial
blood pressure or heart rate throughout the study. After
AA infusion, a significant increase in GFR was observed
only in the control group (+20.6 ± 2.8%; P < 0.05 vs.
basal value), while GFR did not change in CAD. By con-
trast, RPF increased significantly in CAD patients and
controls, reaching 384 ± 27 mL/min/1.73m2 and 540 ±
14 mL/min/1.73m2, respectively. Responsiveness of GFR
and RPF to AA did not differ according to the number
of SCS. No correlations were found between basal val-
ues of RPF and GFR and their respective increments in-
duced by AA infusion in either group. RVR significantly
decreased both in controls (from 0.16 ± 0.01 to 0.12 ±
0.01 mm Hg/mL/min, P < 0.005) and in CAD patients
(from 0.24 ± 0.02 to 0.17 ± 0.01 mm Hg/mL/min, P <
0.005). The single values of GFR and RPF are reported
in Figures 2 and 3.
Follow-up results
After one year, no significant changes in clinical and
laboratory parameters were observed. During the entire
follow-up period, six patients had a single episode of
angina; both after one year and after two years of follow-
up the number of cardiovascular drugs did not change. In
the C group, no cardiovascular event was evident and
no cardiovascular drug was administered. Despite the
loss of patients in both groups, the age and gender re-
mained similar in both groups and the statistical power
still remained adequate for paired and unpaired com-
parisons. The laboratory data and the results of the re-
nal clearances at the two-year follow-up are reported in
Table 2. No significant modifications of echocardiogra-
phy parameters and, in particular, of ejection fraction,
were observed both in CAD patients and in the control
group after two years before and after AA infusion. Re-
nal longitudinal diameters were similar in controls, while
they decreased in CAD patients (P < 0.005 vs. baseline).
The observed decrement of GFR and RPF in CAD pa-
tients was unrelated to the number of coronary stenoses.
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Fig. 2. Single values of PAH clearance in
CAD patients and in C subjects at baseline
and after AA infusion. Horizontal lines rep-
resent the median values; P values indicate the
statistical difference between baseline and af-
ter AA.
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Fig. 3. Single values of inulin clearance in
CAD patients and in C subjects at baseline
and after AA infusion. Horizontal line repre-
sents the median value; P values indicate the
statistical difference between baseline and af-
ter AA. N.S. NS, not significant.
After AA infusion, RPF increased significantly (+67.7 ±
19.9 mL/min/1.73m2, P = 0.0042) in CAD patients with
a modest, but not significant increase in GFR (+2.8 ±
1.01 mL/min/1.73m2 vs. basal value). In the C group, the
rate of decrease in GFR was less than in CAD patients
(1.9 ± 0.4 mL/year, P < 0.05 vs. basal), while the decrease
of RPF (6.0 ± 1.5 mL/year) was slight and not signifi-
cant. AA infusion elicited a parallel, significant increase
in both RPF (75 ± 5.1 mL/min/1.73m2) and GFR (16 ±
1.4 mL/min/1.73m2).
DISCUSSION
The novel finding of the present study is the presence
in CAD patients of renal hemodynamic abnormalities
despite clinically normal renal function that is associ-
ated with progressive deterioration in GFR. It is known
that CAD is strongly associated with other comorbidi-
ties such as peripheral vascular disease, including changes
in renal vasculature [25–27], and many studies have de-
tailed that the association between cardiovascular co-
morbidities and atherosclerotic renovascular disease is
a frequent cause of chronic renal failure [28]. Specifically,
one study of patients undergoing coronary angiography
for symptomatic CAD reported that 15% of the patients
had significant atherosclerotic renovascular disease [26].
However, at variance with this work, the previous stud-
ies evaluating the relationship between CAD and renal
function did not obtain direct measurements in GFR, as
we did by means of inulin clearance, while RPF was not
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Table 2. Baseline and 2-year follow-up data of 10 controls and 12 CAD patients
Controls Patients
Follow-up Baseline Follow-up Baseline
sGlucose mg/dL 99.1 ± 4 101 ± 2 101 ± 3 100 ± 2
sCreatinine mg/dL 1.07 ± 0.03 1.07 ± 0.04 1.06 ± 0.04 1.27 ± 0.03c
TC mg/dL 1923 ± 35 193 ± 23 205 ± 27 213 ± 29
TRG mg/dL 114 ± 10 120 ± 11 152 ± 16 152 ± 8
SBP mm Hg 136 ± 1.2 138 ± 1.4 138 ± 1.2 139 ± 1.2
DBP mm Hg 78 ± 2.9 80 ± 2.7 83.0 ± 2.9 82.5 ± 2.2
LV EF% 67.2 ± 3.48 67.1 ± 3.94 56.9 ± 2.58 55,6 ± 1.96f
Before AA GFR mL/min/1.73 m2 82.4 ± 1.4 78.8 ± 1.6a 79.7 ± 1.4 69.6 ± 2.3c,h
After AA GFR mL/min/1.73 m2 101 ± 3d 97.9 ± 3.6d 84.4 ± 2.3 72.4 ± 2.6c,h
Before AA RPF mL/min/1.73 m2 449 ± 12.4 437 ± 9.2 257 ± 28 219 ± 24c,i
After AA RPF mL/min/1.73 m2 536 ± 17 527 ± 11e 363 ± 37 287 ± 29b,d,i
Renal LD cm 11.2 ± 0.6 11.1 ± 0.4 10.3 ± 0.43 9.6 ± 0.28c,g
Abbreviations are: SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; TRG, triglycerides; LD, longitudinal diameter; NS, not
significant. Data are mean ± SEM.
P vs. baseline: aP < 0.05; bP < 0.01; cP < 0.005.
P vs. “before AA”: dP < 0.05; eP < 0.005.
P controls vs. patients at follow up: fP < 0.05; gP < 0.01; hP < 0.005; iP < 0.001.
determined at all [29, 30]; this point becomes critical when
considering that in the presence of normal or mild impair-
ment of renal function, serum creatinine–based equations
significantly differ from measured GFR values [31]. Fur-
thermore, most patients included in the previous studies
had a frank nephropathy, as testified by the degree of re-
nal dysfunction and the presence of renal artery stenoses.
Finally, although it has been recently reported that there
is independent association between mild chronic kidney
disease and increased coronary artery calcification scores
[29], this is the first study that evaluates the other side of
the coin, demonstrating that early renal functional ab-
normalities, undetectable by routine clinical investiga-
tions but leading to progressive reduction in GFR, can be
present in patients with CAD. In fact, our CAD patients
had normal serum creatinine levels, normal creatinine
clearances, normal urinalysis, and absence of microalbu-
minuria, as currently defined; however, their UAE lev-
els (in 24-hour urine samples) were higher than the very
low levels (in overnight samples) recently proposed by
Klausen et al to redefine microalbuminuria as a determi-
nant of coronary heart disease [32], thus indirectly sup-
porting the conclusions of these authors.
In order to have an appropriate control group, we in-
cluded a subset of age- and sex-matched healthy individ-
uals, represented by kidney donors without any evidence
of atherosclerotic risk factors. This methodologic design
allowed us to evaluate for the first time the independent
effects of atherosclerosis on renal hemodynamics before
any renal abnormality becomes clinically evident. Basal
RPF was about 40% lower in CAD patients than in C
subjects, demonstrating that even in these early stages
of atherosclerosis the vascular disease is not restricted
to coronary arteries, but can also considerably affect the
perfusion of the kidneys.
The smaller kidneys observed at baseline by renal ul-
trasound in CAD patients are probably a consequence of
their chronic hypoperfusion [33]. It is important to un-
derline that despite hypoperfusion, basal GFR was not
significantly lower in CAD than in controls. This find-
ing might be ascribed to an intense efferent glomeru-
lar arteriolar constriction in CAD patients that reduces
glomerular flow egress, thereby promoting an increase
in intraglomerular hydrostatic pressure that limits GFR
decline. The elevated PRA, observed both in supine and
upright position in CAD patients, strongly suggests that in
these patients the renin-angiotensin system is activated,
likely because of renal hypoperfusion. This activation
might result in enhanced generation of angiotensin II,
which induces a preferential increase in efferent arterio-
lar resistance so that GFR is maintained at near-normal
levels even in the presence of renal hypoperfusion. Be-
sides an excessive renal production of angiotensin II, it
is possible to hypothesize a decreased renal synthesis of
nitric oxide, as testified by the impaired renal vasodila-
tory response to AA infusion. Indeed, both experimental
and clinical studies in different pathophysiologic condi-
tions, characterized by normal GFR but impaired renal
functional reserve (RFR), have proposed RFR as a reli-
able test to assess in vivo the angiotensin II/nitric oxide
balance [34, 35]; specifically, the reduction or absence of
GFR increase after AA infusion has been attributed to
increase in angiotensin II and/or decrease in nitric oxide
production.
Of note, in CAD patients, the renal involvement was
likely microvascular since the presence of relevant alter-
ations in renal arterial vessels was excluded by angiog-
raphy. The observed changes in renal hemodynamics are
similar to those detected by our group in kidney-donor
subjects with advanced age [15], in whom atherosclerotic
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changes of renal arterioles were documented. This find-
ing, therefore, supports an early renal arteriolosclerosis
in CAD patients with normal renal function.
To evaluate the long-term effects of the hemodynamic
alterations we repeated the clearance studies after two
years. In CAD patients, RPF further decreased by about
15% versus baseline in the absence of any variation of
systemic hemodynamics, reaching a value that was half of
that detected in controls. However, at variance with basal
conditions, worsening of renal perfusion was associated
with a proportional decline in GFR.
The rate of decrement of GFR appears fairly higher
than in other slowly progressive nephropathies. How-
ever, it should be considered that, at variance with those
included in the other study, our patients were recruited
from a geriatric population. In normal elderly subjects, in
fact, GFR decreases 0.75 to 1.05 mL/min per year [15].
Therefore, the accelerated decline of GFR observed in
our patients could be explained by a synergic effect of ag-
ing and renal hemodynamic dysfunction and indicates a
loss over time of the efficacy of the compensatory mech-
anism dependent on vasoconstriction of glomerular ef-
ferent arteriole. Since no change in ejection fraction was
observed at the follow-up in both groups, a decline of this
parameter does not appear to be involved in the loss of re-
nal function in our patients. The unchanged impairment
of RFR, in fact, suggests that the angiotensin II–nitric
oxide imbalance still accounted for efferent vasoconstric-
tion; this mechanism, however, was not effective anymore
at counteracting the additional decrement of RPF. The
progressive impairment of GFR caused by chronic is-
chemia was likely irreversible as testified by the gradual
reduction in kidney size [36]. Therefore, CAD patients,
even in the absence of renal artery stenoses and GFR
impairment at baseline, are prone to develop progressive
renal hemodynamic dysfunction. On this basis, a different
approach to diagnose renal hypoperfusion and eventu-
ally improve renal perfusion in CAD patients should take
place quite early. The number of coronary stenoses can
be initially of some diagnostic utility being correlated to
the severity of renal hypoperfusion, but it does not seem
to be predictive of the long-term changes of RPF and
GFR. An early diagnosis of chronic renal ischemia can
be made evaluating renal perfusion that can be reliably
measured in clinical practice by using scintigraphic meth-
ods, such as quantitative Tc-99m DTPA scintigraphy and
dynamic c camera imaging. Therefore, the current rec-
ommendations of K-DOQI about the early detection of
chronic kidney disease [37] might include the measure-
ment of renal plasma flow in patients with atherosclerotic
disease as a marker of renal damage, as well as cystatin C
measurement, as recently reported by a study in patients
aged over 65 years [38]. If these patients are identified,
they could be treated with a multi-approach therapy, in-
cluding drugs with systemic and renal vasodilating prop-
erties, such as calcium antagonists [39], in association with
ACE inhibitors or ARA and drugs with anti-lipidemic
and anti-inflammatory actions, to provide more effective
nephroprotection [40]. In this regard, it has been demon-
strated by our group that in patients with impaired renal
functional reserve and mild heart failure the treatment
with ACE inhibitors or ARA restores the renal functional
reserve [14].
The results of this study should be carefully interpreted
because of some limitations: (1) no follow-up catheteri-
zation data to assess for development of renovascular
disease were available, and the mechanism of decrease
in GFR is hypothetical; (2) the loss of some patients dur-
ing the follow-up can represent a relative limitation, de-
spite the statistical power of the sample still remaining
adequate.
CONCLUSION
Our data demonstrate that in patients with CAD an
early reduction in renal perfusion may occur likely be-
cause of activation in renin-angiotensin system, despite
clinically normal GFR and absence of significant renal
artery stenoses. An early identification of these patients
is required since they are at risk of progressive renal
dysfunction.
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